SEC Form 4 · accession 0001209191-19-003735
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Lee Flynn
Officer — Chief Scientific Officer
Period of report
Jan 11, 2019
Accepted (ET)
Jan 15, 2019 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 11, 2019 | M | 300 | $1.89 | A | 300 | D | |
| Common Stock | Jan 11, 2019 | S | 300 | $26.00 | D | 0 | D | |
| Common Stock | holding | — | — | — | 147,049 | I | By Biochenomix, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.89 | Jan 11, 2019 | M | 300 | D | — | Dec 17, 2025 | Common Stock | 300 | 625,307 | D |
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.